KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Common Equity (2016 - 2025)

Historic Common Equity for West Pharmaceutical Services (WST) over the last 17 years, with Q4 2025 value amounting to $3.2 billion.

  • West Pharmaceutical Services' Common Equity rose 1840.58% to $3.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $3.2 billion, marking a year-over-year increase of 1840.58%. This contributed to the annual value of $3.2 billion for FY2025, which is 1840.58% up from last year.
  • As of Q4 2025, West Pharmaceutical Services' Common Equity stood at $3.2 billion, which was up 1840.58% from $3.1 billion recorded in Q3 2025.
  • In the past 5 years, West Pharmaceutical Services' Common Equity ranged from a high of $3.2 billion in Q4 2025 and a low of $1.8 billion during Q1 2021
  • Its 5-year average for Common Equity is $2.6 billion, with a median of $2.7 billion in 2024.
  • Per our database at Business Quant, West Pharmaceutical Services' Common Equity skyrocketed by 2812.26% in 2021 and then plummeted by 689.69% in 2024.
  • Over the past 5 years, West Pharmaceutical Services' Common Equity (Quarter) stood at $2.3 billion in 2021, then grew by 14.97% to $2.7 billion in 2022, then rose by 7.3% to $2.9 billion in 2023, then fell by 6.9% to $2.7 billion in 2024, then rose by 18.41% to $3.2 billion in 2025.
  • Its Common Equity stands at $3.2 billion for Q4 2025, versus $3.1 billion for Q3 2025 and $2.9 billion for Q2 2025.